Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II

    Research output: Contribution to journalArticle

    Abstract

    Pneumococcal polysaccharide vaccine should be given to patients with diabetes at diagnosis with up to two further 5-yearly doses. In 1465 representative community-based Fremantle Diabetes Study Phase II participants with type 2 diabetes (mean age 66 years, 52% males), 624 (42.6%) self-reported pneumococcal vaccination in the previous 5 years. Vaccination was significantly associated with insulin treatment and cardiovascular pharmacotherapy, suggesting that medical reviews provide the opportunity to address sub-optimal coverage.

    Original languageEnglish
    Pages (from-to)1206-1210
    Number of pages5
    JournalInternal Medicine Journal
    Volume47
    Issue number10
    DOIs
    Publication statusPublished - 1 Oct 2017

    Fingerprint Dive into the research topics of 'Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II'. Together they form a unique fingerprint.

  • Cite this